Sussex Formulary

Drug Status Key

  • Non-Specialist Drugs
  • Specialist recommendation (or initiation where noted)
  • Specialist Initiation WITH Shared Care Guidelines
  • Specialist ONLY Drugs
  • Mixed Status - See individual drug entries for more details

Preferences

  • First Line
  • Second Line
  • Third Line
  • No Preference

5.6.1 Coronavirus

Molnupiravir

Black Triangle { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

For treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test, only if:

they have 1 or more risk factors for progression to severe COVID-19

and

both nirmatrelvir plus ritonavir and sotrovimab are contraindicated or unsuitable

(NICE TA1056)

Molnupiravir 200mg capsules

Pack
40 capsule

Nirmatrelvir + Ritonavir

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Sotrovimab

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Tocilizumab

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }
Where more than one biologic treatment is suitable, it is the responsibility of the provider to ensure the most cost-effective option is selected.
Biosimilars are available which should be used in line with local contracting agreements.
Originator - RoActemra
Biosmilar - Tyenne

Tocilizumab 162mg/0.9ml solution for injection pre-filled disposable devices

Pack
4 pre-filled disposable injection

Tocilizumab 162mg/0.9ml solution for injection pre-filled syringes

Pack
4 pre-filled disposable injection

Tocilizumab 200mg/10ml solution for infusion vials

Pack
1 vial

Tocilizumab 400mg/20ml solution for infusion vials

Pack
1 vial

Tocilizumab 80mg/4ml solution for infusion vials

Pack
1 vial

Remdesivir

Black Triangle { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }